XML 21 R11.htm IDEA: XBRL DOCUMENT
v3.23.3

REVENUES | 9 Months Ended
--- | ---
Sep. 30, 2023
Revenue from Contract with Customer [Abstract] |
REVENUES | REVENUES Disaggregation of Revenues The following table summarizes our Total revenues:
|  | Three Months Ended September 30, 2023 |  | Three Months Ended September 30, 2022
(in millions) |  | U.S. |  | Europe |  | Other International |  | Total |  | U.S. |  | Europe |  | Other International |  | Total
Product sales: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
HIV |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Biktarvy |  | $ | 2,504 |  |  | $ | 313 |  |  | $ | 268 |  |  | $ | 3,085 |  |  | $ | 2,286 |  |  | $ | 278 |  |  | $ | 201 |  |  | $ | 2,766 |
Complera/Eviplera |  | 13 |  |  | 18 |  |  | 3 |  |  | 34 |  |  | 20 |  |  | 21 |  |  | 3 |  |  | 43 |
Descovy |  | 460 |  |  | 25 |  |  | 26 |  |  | 511 |  |  | 444 |  |  | 28 |  |  | 28 |  |  | 500 |
Genvoya |  | 433 |  |  | 47 |  |  | 23 |  |  | 503 |  |  | 502 |  |  | 71 |  |  | 27 |  |  | 600 |
Odefsey |  | 257 |  |  | 74 |  |  | 11 |  |  | 343 |  |  | 276 |  |  | 86 |  |  | 12 |  |  | 374 |
Stribild |  | 18 |  |  | 5 |  |  | 2 |  |  | 25 |  |  | 22 |  |  | 7 |  |  | 3 |  |  | 32 |
Truvada |  | 15 |  |  | 3 |  |  | 4 |  |  | 22 |  |  | 24 |  |  | 3 |  |  | 2 |  |  | 30 |
Revenue share - Symtuza(1) |  | 96 |  |  | 32 |  |  | 3 |  |  | 131 |  |  | 85 |  |  | 40 |  |  | 4 |  |  | 130 |
Other HIV(2) |  | 10 |  |  | 3 |  |  | — |  |  | 13 |  |  | 1 |  |  | 6 |  |  | 5 |  |  | 12 |
Total HIV |  | 3,807 |  |  | 519 |  |  | 341 |  |  | 4,667 |  |  | 3,661 |  |  | 541 |  |  | 285 |  |  | 4,487 |
Oncology |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Cell Therapy |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Tecartus |  | 64 |  |  | 27 |  |  | 4 |  |  | 96 |  |  | 60 |  |  | 20 |  |  | 1 |  |  | 81 |
Yescarta |  | 197 |  |  | 154 |  |  | 40 |  |  | 391 |  |  | 210 |  |  | 91 |  |  | 16 |  |  | 317 |
Total Cell Therapy |  | 261 |  |  | 181 |  |  | 45 |  |  | 486 |  |  | 270 |  |  | 111 |  |  | 17 |  |  | 398 |
Trodelvy |  | 201 |  |  | 62 |  |  | 21 |  |  | 283 |  |  | 139 |  |  | 38 |  |  | 3 |  |  | 180 |
Total Oncology |  | 462 |  |  | 243 |  |  | 65 |  |  | 769 |  |  | 409 |  |  | 149 |  |  | 20 |  |  | 578 |
Liver Disease |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Chronic hepatitis C virus (“HCV”)
Ledipasvir/Sofosbuvir(3) |  | 17 |  |  | 2 |  |  | 4 |  |  | 23 |  |  | 8 |  |  | 5 |  |  | 12 |  |  | 25 |
Sofosbuvir/Velpatasvir(4) |  | 215 |  |  | 76 |  |  | 85 |  |  | 377 |  |  | 241 |  |  | 131 |  |  | 84 |  |  | 455 |
Other HCV(5) |  | 28 |  |  | 7 |  |  | 3 |  |  | 38 |  |  | 34 |  |  | 7 |  |  | 2 |  |  | 44 |
Total HCV |  | 260 |  |  | 85 |  |  | 93 |  |  | 438 |  |  | 283 |  |  | 143 |  |  | 98 |  |  | 524 |
Chronic hepatitis B virus (“HBV”) / Chronic hepatitis delta virus (“HDV”)
Vemlidy |  | 112 |  |  | 9 |  |  | 106 |  |  | 228 |  |  | 129 |  |  | 9 |  |  | 90 |  |  | 228 |
Viread |  | 4 |  |  | 5 |  |  | 12 |  |  | 21 |  |  | 2 |  |  | 5 |  |  | 15 |  |  | 22 |
Other HBV/HDV(6) |  | — |  |  | 19 |  |  | — |  |  | 20 |  |  | — |  |  | 13 |  |  | — |  |  | 14 |
Total HBV/HDV |  | 116 |  |  | 34 |  |  | 119 |  |  | 269 |  |  | 131 |  |  | 28 |  |  | 106 |  |  | 264 |
Total Liver Disease |  | 376 |  |  | 119 |  |  | 211 |  |  | 706 |  |  | 413 |  |  | 170 |  |  | 204 |  |  | 788 |
Veklury |  | 258 |  |  | 65 |  |  | 313 |  |  | 636 |  |  | 336 |  |  | 130 |  |  | 458 |  |  | 925 |
Other |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
AmBisome |  | 12 |  |  | 63 |  |  | 39 |  |  | 115 |  |  | 9 |  |  | 63 |  |  | 33 |  |  | 105 |
Letairis |  | 36 |  |  | — |  |  | — |  |  | 36 |  |  | 43 |  |  | — |  |  | — |  |  | 43 |
Other(7) |  | 34 |  |  | 9 |  |  | 23 |  |  | 65 |  |  | 28 |  |  | 11 |  |  | 13 |  |  | 52 |
Total Other |  | 82 |  |  | 72 |  |  | 62 |  |  | 216 |  |  | 80 |  |  | 75 |  |  | 46 |  |  | 200 |
Total product sales |  | 4,985 |  |  | 1,017 |  |  | 992 |  |  | 6,994 |  |  | 4,900 |  |  | 1,064 |  |  | 1,013 |  |  | 6,978 |
Royalty, contract and other revenues |  | 32 |  |  | 23 |  |  | 1 |  |  | 56 |  |  | 28 |  |  | 37 |  |  | — |  |  | 64 |
Total revenues |  | $ | 5,017 |  |  | $ | 1,040 |  |  | $ | 993 |  |  | $ | 7,051 |  |  | $ | 4,928 |  |  | $ | 1,101 |  |  | $ | 1,013 |  |  | $ | 7,042 |
|  | Nine Months Ended September 30, 2023 |  | Nine Months Ended September 30, 2022
(in millions) |  | U.S. |  | Europe |  | Other International |  | Total |  | U.S. |  | Europe |  | Other International |  | Total
Product sales: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
HIV |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Biktarvy |  | $ | 7,104 |  |  | $ | 920 |  |  | $ | 717 |  |  | $ | 8,741 |  |  | $ | 6,088 |  |  | $ | 807 |  |  | $ | 577 |  |  | $ | 7,472 |
Complera/Eviplera |  | 40 |  |  | 55 |  |  | 9 |  |  | 104 |  |  | 56 |  |  | 76 |  |  | 10 |  |  | 142 |
Descovy |  | 1,314 |  |  | 75 |  |  | 86 |  |  | 1,475 |  |  | 1,152 |  |  | 92 |  |  | 91 |  |  | 1,335 |
Genvoya |  | 1,305 |  |  | 157 |  |  | 81 |  |  | 1,544 |  |  | 1,441 |  |  | 220 |  |  | 103 |  |  | 1,764 |
Odefsey |  | 754 |  |  | 223 |  |  | 33 |  |  | 1,011 |  |  | 763 |  |  | 278 |  |  | 36 |  |  | 1,077 |
Stribild |  | 57 |  |  | 16 |  |  | 6 |  |  | 79 |  |  | 68 |  |  | 23 |  |  | 7 |  |  | 98 |
Truvada |  | 71 |  |  | 10 |  |  | 16 |  |  | 97 |  |  | 77 |  |  | 12 |  |  | 13 |  |  | 102 |
Revenue share - Symtuza(1) |  | 278 |  |  | 101 |  |  | 10 |  |  | 390 |  |  | 251 |  |  | 126 |  |  | 10 |  |  | 388 |
Other HIV(2) |  | 24 |  |  | 11 |  |  | 6 |  |  | 41 |  |  | 11 |  |  | 20 |  |  | 15 |  |  | 45 |
Total HIV |  | 10,949 |  |  | 1,568 |  |  | 965 |  |  | 13,482 |  |  | 9,906 |  |  | 1,653 |  |  | 863 |  |  | 12,422 |
Oncology |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Cell Therapy |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Tecartus |  | 179 |  |  | 83 |  |  | 11 |  |  | 272 |  |  | 160 |  |  | 56 |  |  | 2 |  |  | 217 |
Yescarta |  | 624 |  |  | 408 |  |  | 99 |  |  | 1,130 |  |  | 528 |  |  | 253 |  |  | 42 |  |  | 823 |
Total Cell Therapy |  | 802 |  |  | 491 |  |  | 109 |  |  | 1,402 |  |  | 688 |  |  | 308 |  |  | 44 |  |  | 1,040 |
Trodelvy |  | 551 |  |  | 169 |  |  | 44 |  |  | 764 |  |  | 379 |  |  | 98 |  |  | 8 |  |  | 485 |
Total Oncology |  | 1,354 |  |  | 660 |  |  | 153 |  |  | 2,167 |  |  | 1,067 |  |  | 407 |  |  | 52 |  |  | 1,525 |
Liver Disease |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
HCV
Ledipasvir/Sofosbuvir(3) |  | 29 |  |  | 11 |  |  | 14 |  |  | 54 |  |  | 27 |  |  | 13 |  |  | 43 |  |  | 83 |
Sofosbuvir/Velpatasvir(4) |  | 643 |  |  | 250 |  |  | 266 |  |  | 1,159 |  |  | 629 |  |  | 288 |  |  | 244 |  |  | 1,161 |
Other HCV(5) |  | 80 |  |  | 33 |  |  | 10 |  |  | 123 |  |  | 88 |  |  | 31 |  |  | 7 |  |  | 127 |
Total HCV |  | 751 |  |  | 294 |  |  | 289 |  |  | 1,335 |  |  | 745 |  |  | 332 |  |  | 294 |  |  | 1,371 |
HBV/HDV
Vemlidy |  | 295 |  |  | 28 |  |  | 322 |  |  | 645 |  |  | 306 |  |  | 27 |  |  | 289 |  |  | 622 |
Viread |  | 4 |  |  | 17 |  |  | 40 |  |  | 62 |  |  | 4 |  |  | 17 |  |  | 48 |  |  | 69 |
Other HBV/HDV(6) |  | — |  |  | 50 |  |  | — |  |  | 51 |  |  | 1 |  |  | 41 |  |  | — |  |  | 42 |
Total HBV/HDV |  | 299 |  |  | 96 |  |  | 363 |  |  | 758 |  |  | 311 |  |  | 85 |  |  | 337 |  |  | 733 |
Total Liver Disease |  | 1,051 |  |  | 390 |  |  | 652 |  |  | 2,093 |  |  | 1,056 |  |  | 417 |  |  | 631 |  |  | 2,104 |
Veklury |  | 607 |  |  | 227 |  |  | 630 |  |  | 1,465 |  |  | 1,179 |  |  | 560 |  |  | 1,166 |  |  | 2,905 |
Other |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
AmBisome |  | 39 |  |  | 192 |  |  | 150 |  |  | 381 |  |  | 48 |  |  | 192 |  |  | 140 |  |  | 380 |
Letairis |  | 106 |  |  | — |  |  | — |  |  | 106 |  |  | 135 |  |  | — |  |  | — |  |  | 135 |
Other(7) |  | 91 |  |  | 31 |  |  | 49 |  |  | 171 |  |  | 91 |  |  | 52 |  |  | 35 |  |  | 178 |
Total Other |  | 236 |  |  | 224 |  |  | 199 |  |  | 658 |  |  | 275 |  |  | 244 |  |  | 174 |  |  | 693 |
Total product sales |  | 14,196 |  |  | 3,069 |  |  | 2,599 |  |  | 19,864 |  |  | 13,482 |  |  | 3,281 |  |  | 2,887 |  |  | 19,650 |
Royalty, contract and other revenues |  | 57 |  |  | 77 |  |  | 4 |  |  | 138 |  |  | 140 |  |  | 98 |  |  | 4 |  |  | 242 |
Total revenues |  | $ | 14,253 |  |  | $ | 3,146 |  |  | $ | 2,603 |  |  | $ | 20,002 |  |  | $ | 13,622 |  |  | $ | 3,378 |  |  | $ | 2,891 |  |  | $ | 19,892 |
_______________________________ (1) Represents our revenue from cobicistat (“C”), emtricitabine (“FTC”) and tenofovir alafenamide (“TAF”) in Symtuza (darunavir/C/FTC/TAF), a fixed dose combination product commercialized by Janssen Sciences Ireland Unlimited Company (“Janssen”). (2) Includes Atripla, Emtriva, Sunlenca and Tybost. (3) Amounts consist of sales of Harvoni and the authorized generic version of Harvoni sold by our separate subsidiary, Asegua Therapeutics LLC. (4) Amounts consist of sales of Epclusa and the authorized generic version of Epclusa sold by our separate subsidiary, Asegua Therapeutics LLC. (5) Includes Vosevi and Sovaldi. (6) Includes Hepcludex and Hepsera. (7) Includes Cayston, Jyseleca, Ranexa and Zydelig. Revenues from Major Customers The following table summarizes revenues from each of our customers who individually accounted for 10% or more of our Total revenues:
|  | Three Months Ended |  | Nine Months Ended
|  | September 30, |  | September 30,
(as a percentage of total revenues) |  | 2023 |  | 2022 |  | 2023 |  | 2022
Cencora, Inc. (formerly known as AmerisourceBergen Corporation) |  | 19 | % |  | 18 | % |  | 19 | % |  | 17 | %
Cardinal Health, Inc. |  | 25 | % |  | 25 | % |  | 26 | % |  | 25 | %
McKesson Corporation |  | 22 | % |  | 22 | % |  | 21 | % |  | 20 | %
Revenues Recognized from Performance Obligations Satisfied in Prior Years The following table summarizes revenues recognized from performance obligations satisfied in prior years:
|  | Three Months Ended |  | Nine Months Ended
|  | September 30, |  | September 30,
(in millions) |  | 2023 |  | 2022 |  | 2023 |  | 2022
Revenue share with Janssen and royalties for licenses of intellectual property |  | $ | 166 |  |  | $ | 192 |  |  | $ | 517 |  |  | $ | 573 |
Changes in estimates |  | $ | 111 |  |  | $ | 207 |  |  | $ | 347 |  |  | $ | 452 |
Contract Balances The following table summarizes our contract balances:
(in millions) |  | September 30, 2023 |  | December 31, 2022
Contract assets(1) |  | $ | 123 |  |  | $ | 171 |
Contract liabilities(2) |  | $ | 68 |  |  | $ | 102 |
________________________________ (1) Consists of unbilled amounts primarily from arrangements where the licensing of intellectual property is the only or predominant performance obligation. (2) Generally results from receipt of advance payment before our performance under the contract.

X
- References No definition available. + Details
Name: | us-gaap_RevenueFromContractWithCustomerAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-9 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-10 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-15 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-12 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-12 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-12 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-12 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-12 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-13 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Topic 606 -Publisher FASB -URI https://asc.fasb.org//606/tableOfContent + Details
Name: | us-gaap_RevenueFromContractWithCustomerTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration